Illumina Inc (ILMN)
Illumina Inc (ILMN) carries a ŷRobot AI score of 73 out of 100. The model's fair value estimate is $279.28, 34.9% above the last close of $207.01. The chart signal reads Buy.
| Metric | ILMN |
|---|---|
| AI score | 73 / 100 |
| Chart signal | Buy |
| Fair value estimate | $279.28 |
| Upside to fair value | 34.9% |
| Previous close | $207.01 |
| P/E | 54.12 |
| Price / sales | 7.93 |
| Market cap | $31.68B |
| EPS | 5.36 |
| Revenue growth | -2.0% |
| 1-year price change | 3.7% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about ILMN
Is ILMN overvalued or undervalued right now?
As of Oct 31, 2026, ŷRobot's fair-value model estimates Illumina Inc (ILMN) at $279.28 against a last close of $207.01, implying 34.9% upside to the model's estimate.
Is ILMN's chart signal bullish or bearish?
The chart-signal model classifies ILMN as Bullish as of Nov 13, 2026, with a signal score of 0.19 on a -1 to 1 scale.
What is ILMN's ŷRobot AI score?
ILMN scores 73 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is ILMN stock expensive on P/E and P/S?
ILMN trades at 54.1 times earnings and 7.9 times sales as of Nov 13, 2026.
What does ILMN's seasonal forecast show?
ŷRobot's seasonal forecast curve for ILMN reads +1.4% at 30 days, -0.7% at 90 days, and +3.7% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ILMN growing?
Illumina Inc's revenue growth is -2.0% and free-cash-flow growth is +3.3% on the latest reported figures.
ILMN chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.